Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
| Autor: | Hurvitz, Sara A1 SHurvitz@mednet.ucla.edu, Martin, Miguel2, Symmans, W Fraser3, Jung, Kyung Hae4, Huang, Chiun-Sheng5, Thompson, Alastair M3, Harbeck, Nadia6, Valero, Vicente3, Stroyakovskiy, Daniil7, Wildiers, Hans8, Campone, Mario9, Boileau, Jean-François10, Beckmann, Matthias W11, Afenjar, Karen12, Fresco, Rodrigo13, Helms, Hans-Joachim14, Xu, Jin15, Lin, Yvonne G15, Sparano, Joseph16, Slamon, Dennis1 |
|---|---|
| Zdroj: | Lancet Oncology. Jan2018, Vol. 19 Issue 1, p115-126. 12p. |
| Databáze: | Academic Search Ultimate |
| Externí odkaz: |
|